Physician profile
Thomas J Lang
NPI 1457312332
$27,170.75
in general payments reported to CMS, 2019-2025
52 companies · $4,556 in 2025
The $4,556 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,820 · 2020: $4,235 · 2021: $2,787 · 2022: $3,742 · 2023: $4,192 · 2024: $3,839 · 2025: $4,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $98.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,488.39 |
| Education | $98.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,190.22 | 2019-2025 | Enbrel, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $3,572.02 | 2019-2025 | |
| Abbvie INC. | $3,120.38 | 2019-2025 | |
| Janssen Biotech, INC. | $2,405.14 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $1,643.33 | 2019-2025 | |
| Ucb, INC. | $1,272.15 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $1,096.92 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $1,043.15 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $929.93 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $913.87 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $778.30 | 2019-2025 | Orencia |
| Radius Health, INC. | $729.23 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $712.62 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $455.29 | 2019-2024 | Taltz |
| Organon LLC | $306.86 | 2021-2025 | Renflexis, Hadlima |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.